Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy

Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform

Cimeio Therapeutics, a biotechnology company developing a new approach to cell therapy, today announced that the US Patent Office has issued a key patent on the company’s Shielded-Cell and Immunotherapy Pairs platform.

U.S. Patent No. 11,499,168 covers the method of in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the laboratory of company founder Lukas Jeker, M.D., Ph.D., at the University of Basel, and is licensed exclusively to Cimeio.

This comprehensive intellectual property provides broad protection for our platform. We believe this patent, along with those we’ve filed for our target antigen and immunotherapy portfolio, cements us as a leader in the emerging field of cell shielding and will enable the broad development of our SCIP platform.”

Cimeio CEO Thomas Fuchs

Cimeio uses genome editing to insert different proteins into hematopoietic stem cells or other types of cells, allowing the cells to maintain their function while making them resistant to paired immunotherapy depletion. Cimeio’s platform effectively protected cells from degradation mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells in preclinical studies.

The company is advancing its initial clinical development plans for genetic diseases and hematologic malignancies. As previously mentioned, two papers on the company’s pipeline plans will be presented at the American Society of Hematology meeting in December 2022 in New Orleans.

About Cimeio

Cimeio is a gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs® with the potential for hematopoietic stem cell transplantation. Cimeio’s technology platform is based on the design and expression of modified naturally occurring cell surface proteins in HSCs. These variant versions retain their function but are resistant to depletion when treated with dual immunotherapy with high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop therapies for patients with genetic diseases, hematological malignancies, and severe autoimmune disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *